Hui S Li

US Patent:

20220195407, Jun 23, 2022

Filed:

May 7, 2020

Appl. No.:

17/609244

Inventors:

- Durham NC, US
Hui Li - Apex NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C12N 9/22
C12N 15/10
C12N 15/86

Abstract:

The invention provides engineered meganucleases, derived from I-Crel, which have substitutions at particular positions that increase the activity of the nucleases for recognition sequences containing certain center sequences. The invention also provides methods of cleaving double-stranded DNA using such engineered meganucleases. The invention further provides methods for improving the activity of engineered meganucleases for recognition sequences containing certain center sequences.

US Patent:

20210113616, Apr 22, 2021

Filed:

Apr 11, 2019

Appl. No.:

17/046761

Inventors:

- Durham NC, US
Janel Lape - Wake Forest NC, US
Hui Li - Apex NC, US
Jochen Genschel - Raleigh NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

A61K 35/17
C12N 9/22
C12N 15/86
C07K 14/725

Abstract:

The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.

US Patent:

20190338263, Nov 7, 2019

Filed:

Apr 11, 2019

Appl. No.:

16/381668

Inventors:

- Durham NC, US
Janel Lape - Wake Forest NC, US
Victor Bartsevich - Durham NC, US
Hui Li - Apex NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C12N 9/22
C12N 15/86
A61K 9/16
A61K 47/69

Abstract:

The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12x.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.